To suppress the multifaceted activities of EZH2, including both the canonical and noncanonical activities, a PROTACs technique-based degrader, MS177, has been shown to be fast-acting and more potent in suppressing tumor growth.49 This surely represents a promising therapeutic strategy for the development of EZH2 inhibitors. The gene discussed is EZH2; the disease is neoplasm.